Predictive value of circulating N-terminal pro-brain natriuretic peptide in patients after treatment of Hodgkin lymphoma (a 3-year prospective study)

Authors

  • B. B. Samura Zaporizhzhia State Medical University, Ukraine,

DOI:

https://doi.org/10.14739/2310-1237.2017.3.118732

Keywords:

NT-proBNP, cardiovascular events, Hodkin lymphoma, prognosis

Abstract

We aimed to evaluate the prognostic value of circulating N-terminal pro-brain natriuretic peptide (NT-proBNP) in appearance of cardiovascular events in patients after treatment of Hodgkin lymphoma.

Methods: Blood samples for biomarkers measurements were collected. ELISA method for measurements of circulating level of NT-proBNP was used.

Results: During observation period progression of Hodgkin lymphoma was proved in 8 (22.2%) patients, 4 (11.1%) persons were excluded for poor follow-up. Thirty four cumulative clinical events occurred in 11 patients (30.6%) within the follow-up, with their distribution being as follows: 2 cardiovascular deaths, 16 cardiac arrhythmias, 6 cardiac ischemic events, 1 stroke, 4 chronic heart failures and 5 hospital admissions for cardiovascular reasons. 4 deaths were not related with cardiovascular pathology or cardiovascular reasons.

Medians of circulating NT-proBNP levels in free-events subject cohort and subject cohort with cardiovascular events were 5.68 (2.34-7.97) pg/ml and 13.60 (4.83-17.67) pg/ml (р=0.072).  The differences in circulating NT-proBNP levels depending on appearance of heart failure during 3 years were significant. Medians of circulating NT-proBNP levels in patients without heart failure and patients with heart failure were 5.68 (3.21-9.65) pg/ml and 27.09 (21.7-29.59) pg/ml (р<0,001). NT-proBNP positively correlated with ejection fraction of left ventricle (r = -0,503, р = 0,024).

In multivariate logistic regression circulating NT-proBNP independently predicted cumulative cardiovascular events (odds ratio = 1,179; 95% CI = 1,043–1,334; р = 0.008) within 3 years of observation period.

Conclusion: During 3 years after treatment of Hodgkin lymphoma 55% of patients experienced cardiovascular events. Much higher levels of circulating NT-proBNP were found in patients with heart failure in comparing with patients without heart failure. Among patients after treatment of Hodgkin lymphoma increased circulating NT-proBNP may associate with increased cumulative cardiovascular events during 3 years.

References

  1. Abrahamsen, A. F., Loge, J. H., Hannisdal, E., Holte, H., & Kvaløy, S. (1998) Socio-medical situation for long-term survivors of Hodgkin's disease: a survey of 459 patients treated at one institution. Eur. J. Cancer., 34(12), 1865–1870. doi: https://doi.org/10.1016/S0959-8049(98)00269-X
  2. (2015) American Cancer Society. What are the Key Statistics about Hodgkin Disease? Retrieved from http://www.cancer.org/cancer/hodgkindisease/detailedguide/hodgkin-disease-key-statistics.
  3. Blaes, A. H., Rehman, A., Vock, D. M., Luo, X., Menge, M., Yee, D., et al. (2015) Utility of high-sensitivity cardiac troponin T in patients receiving anthracycline chemotherapy. Vasc. Health Risk Manag, 24(11), 591–594. doi: 10.2147/VHRM.S89842
  4. Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol., 32(27), 3059–3068. doi: 10.1200/JCO.2013.54.8800
  5. Favier, O., Heutte, N., Stamatoullas-Bastard, A., Carde, P., Van't Veer, M. B., Aleman, B. M., et al. (2009) European Organization for Research and Treatment of Cancer (EORTC) Lymphoma Group and the Groupe d'Etudes des Lymphomes de l'Adulte (GELA) Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials. Cancer, 115(8), 1680–1691. doi: 10.1002/cncr.24178.
  6. Johnson, P., Federico, M., Kirkwood, A., Fosså, A., Berkahn, L., Carella, A., et al. (2016) Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. N. Engl. J. Med., 374(25), 2419–2429. doi: 10.1056/NEJMoa1510093
  7. Kiserud, C. E., Loge, J. H., Fosså, A., Holte, H., Cvancarova, M., & Fosså, S. D. (2010) Mortality is persistently increased in Hodgkin's lymphoma survivors. Eur. J. Cancer, 46(9), 1632–1639. doi: 10.1016/j.ejca.2010.02.010
  8. Krawczuk-Rybak, M., Dakowicz, L., Hryniewicz, A., Maksymiuk, A., Zelazowska-Rutkowska, B., & Wysocka, J. (2011) Cardiac function in survivors of acute lymphoblastic leukaemia and Hodgkin's lymphoma. Paediatr. Child. Health, 47(7), 455–459. doi: 10.1111/j.1440-1754.2010.01991.x
  9. Radford, J., Illidge, T., Counsell, N., Hancock, B., Pettengell, R., Johnson, P., et al. (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N. Engl. J. Med., 372(17), 1598–1607. doi: 10.1056/NEJMoa1408648
  10. Sivkovich, S. O., & Kysel'ova, O. A. (2012) Diagnostics, prognosis factors, and treatment of malignant lymphoproliferative disease, Hodgkin Disease. Lik. Sprava, 1–2, 56–63.
  11. van Nimwegen, F. A., Schaapveld, M., Janus, C. P., Krol, A. D., Petersen, E. J., Raemaekers, J. M., et al. (2015) Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern. Med., 175(6), 1007–1017. doi: 10.1001/jamainternmed.2015.1180.

Downloads

How to Cite

1.
Samura BB. Predictive value of circulating N-terminal pro-brain natriuretic peptide in patients after treatment of Hodgkin lymphoma (a 3-year prospective study). Pathologia [Internet]. 2017Dec.22 [cited 2026May20];14(3). Available from: https://pat.zsmu.edu.ua/article/view/118732

Issue

Vol. 14 No. 3 (2017)

Section

Original research

License

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Лицензия Creative Commons